175 related articles for article (PubMed ID: 20332140)
1. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.
Vilmar AC; Santoni-Rugiu E; Sørensen JB
Ann Oncol; 2010 Sep; 21(9):1817-1824. PubMed ID: 20332140
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
Hsu C; Kuo SH; Hu FC; Cheng AL; Shih JY; Yu CJ; Lin CC; Huang TC; Yang PC; Yang CH
Lung Cancer; 2008 Dec; 62(3):334-43. PubMed ID: 18450322
[TBL] [Abstract][Full Text] [Related]
3. [Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
Zhang L; Liu T; Zhang JQ
Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):212-6. PubMed ID: 21575522
[TBL] [Abstract][Full Text] [Related]
4. Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).
Lee SM; Falzon M; Blackhall F; Spicer J; Nicolson M; Chaudhuri A; Middleton G; Ahmed S; Hicks J; Crosse B; Napier M; Singer JM; Ferry D; Lewanski C; Forster M; Rolls SA; Capitanio A; Rudd R; Iles N; Ngai Y; Gandy M; Lillywhite R; Hackshaw A
J Clin Oncol; 2017 Feb; 35(4):402-411. PubMed ID: 27893326
[TBL] [Abstract][Full Text] [Related]
5. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
[TBL] [Abstract][Full Text] [Related]
6. Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin.
Qiu ZQ; Zhao K
Asian Pac J Cancer Prev; 2014; 15(17):7303-7. PubMed ID: 25227833
[TBL] [Abstract][Full Text] [Related]
7. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Ren S; Zhou S; Zhang L; Xu J; Lv M; Zhang J; Zhou C; Zhang J
Cancer Invest; 2010 Dec; 28(10):1078-83. PubMed ID: 20504223
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101).
Comella P; Filippelli G; De Cataldis G; Massidda B; Frasci G; Maiorino L; Putzu C; Mancarella S; Palmeri S; Cioffi R; Roselli M; Buzzi F; Milia V; Gambardella A; Natale D; Bianco M; Ghiani M; Masullo P;
Ann Oncol; 2007 Feb; 18(2):324-30. PubMed ID: 17071935
[TBL] [Abstract][Full Text] [Related]
9. ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial.
Vilmar A; Santoni-Rugiu E; Sørensen JB
Eur J Cancer; 2010 Jun; 46(9):1554-62. PubMed ID: 20395129
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer.
Sad LM; Younis SG; Elity MM
Med Oncol; 2014 Jul; 31(7):58. PubMed ID: 24935625
[TBL] [Abstract][Full Text] [Related]
12. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
[TBL] [Abstract][Full Text] [Related]
14. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
Tiseo M; Bordi P; Bortesi B; Boni L; Boni C; Baldini E; Grossi F; Recchia F; Zanelli F; Fontanini G; Naldi N; Campanini N; Azzoni C; Bordi C; Ardizzoni A;
Br J Cancer; 2013 Apr; 108(8):1695-703. PubMed ID: 23549037
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine, vinorelbine, and Cisplatin in the treatment of advanced nonsmall cell lung cancer.
Hasturk S; Hatabay N; Ece F; Karatasli M; Hanta I
Am J Clin Oncol; 2009 Jun; 32(3):280-5. PubMed ID: 19433960
[TBL] [Abstract][Full Text] [Related]
16. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
[TBL] [Abstract][Full Text] [Related]
17. ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer.
Han JY; Lee GK; Lim KY; Lee YJ; Nam BH; Lee JS
Cancer Res Treat; 2017 Jul; 49(3):678-687. PubMed ID: 27737534
[TBL] [Abstract][Full Text] [Related]
18. Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
Chen LK; Liang Y; Yang QY; Xu F; Zhou NN; Xu GC; Liu GZ; Wei WD
Asian Pac J Cancer Prev; 2012; 13(5):1863-7. PubMed ID: 22901137
[TBL] [Abstract][Full Text] [Related]
19. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer.
Villalobos M; Czapiewski P; Reinmuth N; Fischer JR; Andreas S; Kortsik C; Serke M; Wolf M; Neuser P; Reuss A; Schnabel PA; Thomas M
Med Oncol; 2018 Jun; 35(7):106. PubMed ID: 29905882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
